trial

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

NCTId NCT03568500
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 44 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2019-05-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
44 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2018-05-21
Primary completion
2019-05-21
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Digital Medicine SystemAripiprazoleOlanzapineQuetiapineRisperidone

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

5 total
Chertsey, United KingdomLondon, United KingdomNewcastle upon Tyne, United KingdomOxford, United KingdomSouthampton, United Kingdom

Facts & assertions

4 sourced
Enrollment
44
Phase
PHASE4
Primary Completion Date
2019-05-21
Status
COMPLETED
relationships
The graph out of here
drug
Digital Medicine System
drug
Aripiprazole
drug
Olanzapine
drug
Quetiapine
drug
Risperidone
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication